Company History
2017 Established the Protein and Peptide Drug Application Engineering Technology Center at the Institute of Advanced Technology, USTC.
2018 Initiated KS-V Peptide in collaboration with IAT, USTC, and Hefei High-tech Construction Investment Group.
2019 Achieved first prize in "Creative China" Hefei Innovation and Entrepreneurship Competition.
2020 Collaborated with Suzhou Innovation Institute, established Suzhou branch, and joined Suzhou Research Institute's incubation platform.
Co-founded "Peptide Drug Research and Development Center" with Shanghai Institute of Pharmacy and Suzhou Innovation Institute.
Organized the 16th Chinese International Peptide Symposium (CPS2020).
2021 Selected for Anhui Innovation and Entrepreneurship Project, established Shanghai Marketing Center.
Invited to 2021 Torch Science and Technology Achievements Direct Train (Anhui Station) and hosted the Yangtze River Delta Artificial
Intelligence Innovative Drug R&D Industry Summit.
2021-2022 Completed angel round financing and round A financing.
2022 Unveiled Anhui Province Innovative Drug Concept Verification Center, established wholly-owned subsidiary KS-Changli.
2019-2022 Recognized as "Young Eagle Enterprise" for four consecutive years, National High-tech Enterprise, Hefei key enterprise, and more.
2023 Relocated KS-V Peptide to the National Big Data Health Industrial Park.
Corporate Philosophy
KS-V Peptide culture
Vision ：Global Leader in Peptide Oriented Drug Discovery and Technological Innovation Services
Mission ：Innovation To Help Drug Research And Development Cooperation To Promote Healthy Life
Value： Innovation，Focus，Service and Win-win
In the era of innovative drug development, KS-V Peptide will adhere to the three-pillar strategy of "core tool products + technical services + innovative research and development," integrating highly developed structural and chemical underlying platform technologies. We aim to provide comprehensive support for research institutions and industrial enterprises engaged in the modernization of innovative drug development in China and globally. Our services span from research innovation to outcome transformation, drug development, preclinical research, and early clinical stages, all in accordance with international regulatory standards.
Covering innovative products and customized service needs from laboratory, preclinical to early clinical stages, we assist clients in transforming drug development from the genetic level into clinical drug molecules. We highly focus on and advance the development of the next generation of innovative drugs targeting unmet clinical needs.
KS-V Peptide Discovery Services Platform（KPDS™）
Long peptide synthesis and refolding technology 
High-quality target protein generation for screening to secure success from the source
In-house libraries:linear,mono-,bi- and multi-cyclic peptide phage libraries, from 7 to 30 amino acids,innovative DNA encoded library
Various peptide modification and optimization methods to improve the peptide stability and binding affinity
